Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SYL18001
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sylentis, PharmaMar Group, Initiates a Phase I Clinical Trial with SYL1801 For Retinal Diseases
Details : This is a Phase I clinical trial involving 36 healthy volunteers and will be carried out at the Ramón y Cajal University Hospital in Madrid (Spain). This study will evaluate the safety of SYL1801 at diff...
Brand Name : SYL18001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 18, 2021
Lead Product(s) : SYL18001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?